Kymera Therapeutics, Inc.
KYMR
$81.21
$1.612.02%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 39.21M | 43.73M | 44.71M | 58.89M | 47.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.21M | 43.73M | 44.71M | 58.89M | 47.07M |
| Cost of Revenue | 316.57M | 304.55M | 290.87M | 271.68M | 240.25M |
| Gross Profit | -277.36M | -260.82M | -246.16M | -212.80M | -193.18M |
| SG&A Expenses | 68.19M | 67.58M | 65.70M | 65.43M | 63.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 384.76M | 372.14M | 356.57M | 337.12M | 303.78M |
| Operating Income | -345.55M | -328.40M | -311.86M | -278.23M | -256.71M |
| Income Before Tax | -311.35M | -295.12M | -275.43M | -240.88M | -223.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -311.35 | -295.12 | -275.43 | -240.88 | -223.86 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -311.35M | -295.12M | -275.43M | -240.88M | -223.86M |
| EBIT | -345.55M | -328.40M | -311.86M | -278.23M | -256.71M |
| EBITDA | -338.83M | -321.54M | -305.06M | -271.67M | -250.74M |
| EPS Basic | -3.68 | -3.60 | -3.48 | -3.10 | -2.97 |
| Normalized Basic EPS | -2.27 | -2.22 | -2.17 | -1.94 | -1.81 |
| EPS Diluted | -3.68 | -3.60 | -3.48 | -3.10 | -2.97 |
| Normalized Diluted EPS | -2.27 | -2.22 | -2.17 | -1.94 | -1.81 |
| Average Basic Shares Outstanding | 337.81M | 327.88M | 316.71M | 309.32M | 299.94M |
| Average Diluted Shares Outstanding | 337.81M | 327.88M | 316.71M | 309.32M | 299.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |